This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (16)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Sandra Weintraub, PhD; M.-Marsel Mesulam, MD; Robert Auty, PhD; Robin Baratz, MA; Barbara N. Cholakos, RD; Lissa Kapust, MSW; Bernard Ransil, MD; John G. Tellers, MD
Charles A. Dana Research Institute Beth Israel Hospital 330 Brookline Ave Boston, MA 02215

Marilyn S. Albert, PhD
Susan LoCastro

Mark Moss, PhD
Department of Psychiatry Massachusetts General Hospital Boston, MA 02114

Arch Neurol. 1983;40(8):527-528.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Alzheimer's disease has been associated with a defect in cortical cholinergic pathways,^1-4 and several reports have appeared within the past five years concerning the use of lecithin, a cholinergic agonist, in treating the associated symptoms.^5-10 With the exception of a recent report by Dysken et al,¹¹ most studies have been of a preliminary nature, lacking adequate controls for the duration of the illness, age of the subjects, placebo effects, dose-dependent effects, and plasma choline levels. Mild improvements in learning and retention have been observed, but in none of the studies reported to date, to our knowledge, has lecithin been shown to alter substantially behavior or the course of the disease. We report the results of a six-month study in which lecithin (Phospholipon-100) (95% phosphatidylcholine) and a placebo were administered in a double-blind crossover protocol to 13 patients with Alzheimer's disease.

Patients and Methods.

—Seven . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?